LI's Kabco agrees to federal compliance
An Amityville pharmaceutical company has agreed to stop violating federal laws covering the manufacture of dietary supplements, federal law enforcement officials said.
A person answering the telephone Wednesday evening at Kabco Pharmaceuticals Inc. said its offices were open but its production was halted. The person didn't identify himself.
The U.S. Department of Justice said Monday that a federal judge had approved a consent decree under which Kabco and its president and chief executive Abu Kabir will cease violating the Federal Food, Drug and Cosmetic Act.
Under the decree, the defendants agreed to stop manufacturing and distributing dietary supplements until, among other corrective actions, the company demonstrates to the U.S. Food and Drug Administration that it is meeting the quality, safety and labeling standards required by law.
The consent decree also requires the defendants to engage "appropriate, independent outside oversight to ensure compliance," the Justice Department said.
Government officials took the company to court after Food and Drug Administration inspections allegedly found that Kabco distributed dietary supplements, including Brewers Yeast Tablets, Dandelion Root Capsules, Night-Time Herb Capsules, Inositol Calcium & Magnesium Capsules, Vitamin C-500 with Rose Hips Time-Released Tablets and Joint All Capsules, that did not meet product specifications.
The government also alleged that Kabco did not review and investigate product complaints, failed to hold dietary supplements under conditions designed to prevent product mix-ups and included unlabeled raw ingredients in their dietary supplements, including one that could cause a serious adverse health reaction in persons allergic to milk.
A January Dun & Bradstreet listing for Kabco said it was incorporated in 1986 and has 170 employees.